Contify — Recent Moves (15 tracked, last 90 days)

Contify, a market and competitive intelligence (M&CI) platform, has been aggressively refining its product and go-to-market strategy over the past two months. With 15 tracked moves since late June 2026, the company is signaling a clear pivot toward AI-driven, prescriptive intelligence and a sharper focus on the pharmaceutical sector. These moves matter because they reveal how Contify is repositioning itself in a crowded intelligence market, betting on vertical specialization and AI answer engine visibility to differentiate.

For competitive intelligence professionals, Contify's recent activity offers a window into the evolving demands of the market—where real-time, AI-integrated insights are becoming table stakes, and where industry-specific frameworks are gaining traction. Understanding Contify's trajectory is essential for anyone tracking the competitive landscape of AI-powered market intelligence.

Theme 1: AI-Centric Product Evolution and Rebranding
Contify has consistently enhanced its AI capabilities, culminating in a redesigned dashboard and upgraded Athena AI engine in early August 2026. The company has also rebranded its AI value proposition from mere efficiency to 'prescriptive strategic foresight' (late June), signaling a shift toward delivering actionable, forward-looking insights. This is reinforced by the launch of a 27-minute guide on AI-driven CI reporting and the quantification of Athena's performance benchmarks. The pattern suggests Contify is doubling down on AI as its core differentiator, aiming to move beyond data aggregation to provide strategic counsel.

Theme 2: Vertical Specialization in Pharma and Diagnostics
Contify has made a series of moves targeting the pharmaceutical and diagnostics sectors. In late July, it launched a diagnostics-specific intelligence operating model, followed by a rebranding of its healthcare vertical to 'Pharmaceuticals' in August. It also began targeting pharma M&A teams with contextual competitor acquisition analysis. These moves indicate a deliberate strategy to own the pharma intelligence niche, offering tailored frameworks and use cases to win over specialized buyers.

Theme 3: Go-to-Market and Organizational Signals
Contify's GTM strategy is evolving, with new marketing hires focused on generative engine optimization (GEO) and answer engine optimization (AEO) to target AI answer engines. The company also introduced the 'M&CI Sources Pentagon' framework to categorize 19 intelligence sources, and repositioned its SWOT framework as a real-time AI asset. However, employee reviews alleging high marketing department turnover (early August) could signal internal friction. Despite this, Contify reports workforce expansion to 350+ professionals, indicating overall growth.

Theme 4: Expanding Use Cases and Thought Leadership
Contify is actively expanding its use cases beyond traditional CI, targeting procurement analytics with automated supplier intelligence for a global consulting firm. It is also investing in thought leadership through guides and frameworks, positioning itself as a knowledge leader in the M&CI space. These moves suggest Contify is broadening its appeal to adjacent functions like procurement while reinforcing its expertise through content marketing.

What to watch: Monitor whether Contify's pharma specialization translates into visible customer wins or partnerships, and whether its AI answer engine strategy yields measurable visibility gains. Also, watch for any fallout from the reported marketing turnover, which could impact its aggressive GTM push. Finally, track how Contify's 'prescriptive foresight' positioning differentiates it in practice from competitors.